Hikal Ltd

Hikal Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 15 June 2026. This change reflects a nuanced improvement in technical indicators alongside a more attractive valuation, despite persistent fundamental challenges and weak long-term financial trends.

Hikal Ltd has exhibited a subtle shift in its technical momentum, moving from a bearish to a mildly bearish stance, as recent price action and indicator signals reveal a complex interplay of bullish and bearish forces. Despite a modest 1.55% gain on 16 Jun 2026, the stock’s broader technical landscape remains mixed, reflecting ongoing challenges within the Pharmaceuticals & Biotechnology sector.

Hikal Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 8 June 2026. This revision reflects deteriorating fundamentals, subdued financial trends, and weak technical signals despite some positive quarterly results. The company’s Mojo Score has declined to 29.0, underscoring growing concerns among institutional investors and market analysts alike.

Hikal Ltd experienced a notable decline today, touching an intraday low of Rs 201.25, reflecting significant price pressure and heightened volatility. The stock underperformed its sector and broader market indices, reversing gains from the previous three sessions.

Hikal Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has demonstrated a notable improvement in its financial performance for the quarter ended March 2026. The company’s financial trend has shifted from flat to positive, driven by exceptional growth in profitability metrics, despite some lingering challenges in longer-term returns and capital efficiency.

Hikal Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Hikal Ltd., a Mumbai-based pharmaceutical and specialty chemicals manufacturer, reported a net profit of ₹14.40 crores for Q4 FY26 (January-March 2026), a dramatic reversal from the ₹5.90 crore loss recorded in the previous quarter. However, the year-on-year comparison reveals a concerning 71.31% decline from the ₹50.20 crore profit posted in Q4 FY25, underscoring persistent operational headwinds that continue to weigh on the company's performance.

Hikal Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 17 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

The Sensex edged up a modest 0.14% on 6 May 2026, but Hikal Ltd surged 7.22%, outperforming its Pharmaceuticals & Biotechnology sector by nearly 5 percentage points. This sharp single-session gain rewrites the short-term narrative for the stock, which has been on a steady upward trajectory over the past week.

Hikal Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 06 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Hikal Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals. Despite a recent uptick in price, the company’s overall technical indicators and fundamental metrics suggest caution for investors navigating this volatile landscape.

Hikal Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s stock price has declined by 2.94% today, reflecting growing investor caution amid mixed technical signals and a deteriorating overall outlook.

Hikal Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 25 April 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Hikal Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent 2.29% rise in its share price to ₹187.30, the company’s overall technical and fundamental outlook remains cautious, with a MarketsMOJO Mojo Grade downgraded to Strong Sell as of 14 Nov 2025.

Hikal Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 14 April 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.